首页> 美国卫生研究院文献>Clinical Interventions in Aging >Managing blood pressure control in Asian patients: safety and efficacy of losartan
【2h】

Managing blood pressure control in Asian patients: safety and efficacy of losartan

机译:管理亚洲患者的血压控制:氯沙坦的安全性和有效性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hypertension is common in Asian populations and is a major cause of cardiovascular diseases. The prevalence of hypertension is increasing in many Asian countries. The overall prevalence of hypertension in India and the People’s Republic of China has been estimated to be 20.6% in men and 22.6% in women. However, the rates of detection, treatment, and control of hypertension remain low in Asia. This reflects a low level of literacy and education, as well as a low level of access to medical care. To overcome these obstacles, strategies targeted at education, promotion, and optimization of medical care, are crucial to achieve target blood pressure control. Angiotensin receptor blockers are one of the first-line treatments for essential hypertension because they confer better cardiovascular outcomes. Losartan has been widely evaluated for the management of hypertension. Although some studies suggested that the blood pressure-lowering effect of losartan is perhaps lower than for other angiotensin receptor blockers, losartan has been demonstrated to be beneficial in terms of renal protection in patients with diabetes, heart failure resulting from either systolic or diastolic dysfunction, and diuretic-induced hyperuricemia. However, most of these data were obtained from Caucasian populations. The efficacy and safety of losartan in Asian populations may be different because of genetic and ethnic variations. Therefore, the efficacy and safety of losartan in Asian patients with hypertension warrant further study.
机译:高血压在亚洲人群中很常见,是导致心血管疾病的主要原因。在许多亚洲国家,高血压的患病率正在上升。据估计,印度和中华人民共和国的高血压总患病率是男性为20.6%,女性为22.6%。但是,在亚洲,高血压的发现,治疗和控制率仍然很低。这反映出识字和教育水平低,以及获得医疗服务的水平低。为了克服这些障碍,针对教育,促进和优化医疗保健的策略对于实现目标血压控制至关重要。血管紧张素受体阻滞剂是原发性高血压的一线治疗方法之一,因为它们可以改善心血管疾病的预后。氯沙坦已被广泛评估用于高血压的治疗。尽管一些研究表明,氯沙坦的降压作用可能低于其他血管紧张素受体阻滞剂,但氯沙坦已被证明对糖尿病患者的肾脏保护有益,因收缩压或舒张功能障碍导致的心力衰竭,和利尿剂引起的高尿酸血症。但是,这些数据大多数是从白种人人群获得的。由于遗传和种族差异,氯沙坦在亚洲人群中的疗效和安全性可能会有所不同。因此,氯沙坦在亚洲高血压患者中的疗效和安全性值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号